Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers. | Biomark Res | 2025 | 40830526 | PubTator, text mining | PubMed |
| A universal monoallelic human leukocyte antigen class II immunopeptidomic platform for defining the immunogenicity potential of therapeutic proteins. | Commun Biol | 2025 | 40830406 | PubTator, text mining | PubMed |
| A Seven-Gene Signature for the Diagnosis of Parkinson's Disease and Immune Infiltration Analysis. | Twin Res Hum Genet | 2025 | 40826924 | PubTator, text mining | PubMed |
| Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. | Blood Res | 2025 | 40815495 | PubTator, text mining | PubMed |
| In-Depth Characterization of L1CAM+ Extracellular Vesicles as Potential Biomarkers for Anti-CD20 Therapy Response in Relapsing-Remitting Multiple Sclerosis. | Int J Mol Sci | 2025 | 40806340 | PubTator, text mining | PubMed |
| Genetics of progressive multifocal leukoencephalopathy: update on case reports with an inborn error of immunity and risk variants found in drug-linked cases. | Front Neurol | 2025 | 40761639 | PubTator, text mining | PubMed |
| Development and validation of a hypoxia-immune-based microenvironment gene signature for predicting survival in non-small cell lung cancer. | Discov Oncol | 2025 | 40759816 | PubTator, text mining | PubMed |
| Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositis. | Sci Rep | 2025 | 40759686 | PubTator, text mining | PubMed |
| Second Generation Tiancimycin-Based Antibody-Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies. | JACS Au | 2025 | 40747030 | PubTator, text mining | PubMed |
| Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study. | Front Oncol | 2025 | 40740863 | PubTator, text mining | PubMed |
| The Efficacy of Polatuzumab Vedotin Targeting CD79B in the Treatment of Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. | Int J Mol Sci | 2025 | 40725080 | PubTator, text mining | PubMed |
| Intravascular Lymphoma: A Unique Pattern Underlying a Protean Disease. | Cancers (Basel) | 2025 | 40723240 | PubTator, text mining | PubMed |
| Refining AI perspectives: assessing the impact of ai curricular on medical students' attitudes towards artificial intelligence. | BMC Med Educ | 2025 | 40713579 | PubTator, text mining | PubMed |
| An unusual pattern observed upon the addition of CD79b to a flow cytometry B-cell lymphoma panel. | Cytometry B Clin Cytom | 2025 | 40657818 | PubTator, text mining | PubMed |
| Favorable impact of zanubrutinib combined with R-CHOP regimen in MYD88-mutated new-diagnosed diffuse large B-cell lymphoma: a retrospective study with propensity score-matched analysis. | Cancer Immunol Immunother | 2025 | 40616640 | PubTator, text mining | PubMed |
| Role of lysine acetylation-related genes in the diagnosis and prognosis of glioma. | Sci Rep | 2025 | 40593136 | PubTator, text mining | PubMed |
| A CD8+ T Cell Infiltration-Driven Prognostic Signature for Gastric Cancer: Bridging Tumor Immunity and Clinical Outcomes. | Int J Genomics | 2025 | 40547199 | PubTator, text mining | PubMed |
| Elucidation of B-cell specific drug immunogenicity liabilities via a novel ex vivo assay. | Front Immunol | 2025 | 40534885 | PubTator, text mining | PubMed |
| Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma. | Hum Pathol | 2025 | 40523447 | PubTator, text mining | PubMed |
| Male Sex, B Symptoms, Bone Marrow Involvement, and Genetic Alterations as Predictive Factors in Diffuse Large B-Cell Lymphoma. | Int J Mol Sci | 2025 | 40507898 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=9